Therapy of oxygen pulses for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer’s Disease (AD), Amiotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, Arthritis and Depression

Abstract

A therapy of oxygen pulses delivered through the pulmonary system of human patient for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer's Disease (AD), Amiotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, Arthritis and Depression is provided. Aspects of the methods including administering to the subjects an effective amount of oxygen as pulses through the respiratory tract are included. Also provided are methods of assessing severity of the disease, mild, moderate, severe, or critical, and oxygen doses and frequencies. The method can be applied to human patient for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer's Disease (AD) Amiotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, arthritis and depression.

Claims

1. A method for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, arthritis and depression, consisting in administering a pulse of oxygen (99-94%) through the respiratory tract using a normal Venturi oxygen mask wherein if the disease is mild would require oxygen pulses of 1 hour, 6 l/min once a day during 10 days, if it is moderate would require oxygen pulses of 1 hour, 6 l/min twice a day during 10 days, if it is severe would require oxygen pulses of 1 hour, 6 l/min, four times a day for 10 days, if it is critical would require oxygen pulses of 1 hour, 6 l/min every 3 hours during 10 days.

2. A method according to claim 1, wherein the oxygen mask is an oxygen mask of high flow high concentration with reservoir nonrebreather where if the disease is mild would require oxygen pulses of 15 minute, 6 l/min once a day during 10 days, if it is moderate would require oxygen pulses of 15 minutes, 6 l/min twice a day during 10 days, if it is severe would require oxygen pulses of 15 minutes, 6 l/min, four times a day for 10 days, if it is critical would require oxygen pulses of 15 minutes, 6 l/min every 3 hours during 10 days.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0194] The pulse oxygen therapy as described therein for treating neurodegenerative diseases (PD, AD, ALS, MS, Arthritis, Lymphedema and Depression) to patients with mild, moderate, severe, or critical conditions may be applied as follow: [0195] 1. The pulse therapy treatment facilities may have sanitary oxygen supply (94-99%) with appropriate oxygen masks and water saturation flask and well isolate and well ventilate places with capacity for supporting a consumption of at least 15 l/min oxygen flow at normal conditions. Patients must have comfortable accommodation (temperature, illumination and sanitary conditions). [0196] 2. As prophylactic treatment (elder patients and/or with chronic diseases) treat patients with 6 l/min oxygen flow for 60 min once a day during 5 days. [0197] 3. As treatment for patients with mild disease (initial symptoms) treat patients with 6 l/min oxygen flow for 60 min once a day during 10 days. [0198] 4. As treatment for patients with moderate disease treat patients with 6 l/min oxygen flow for 60 min twice a day during 10 days. [0199] 5. As treatment for patients with severe disease treat patients with 6 l/min oxygen flow for 60 min four time a day during 10 days. [0200] 6. As treatment for patients with critical disease treat patients with 6 l/min oxygen flow for 60 min every 3 hours during 10 days.

[0201] Control of patients (arterial pressure, temperature) must be made by certificate medical personnel.

Examples

[0202] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. The following examples are illustrative only and are not a limitation on the invention described herein:

[0203] An elder patient with Parkinson Disease (72-year-old) diagnosed in 2010 (moderate conditions) was treated using method as N.sup.o 4 above, and recovered after 5 days. After 12 months no AD symptoms has developed.

[0204] An elder patient with Lymphedema (73 years old) after a cancer radiotherapy treatment with severe limbs inflammation was treated using method as N.sup.o 4 above, and begin recovers after 5 days, after 10 days a notable recuperation takes place. After 11 months no limbs inflammation has developed.

[0205] An elder patient with Arthritis (severe deformation in hands) (72-year-old) was treated using method as N.sup.o 4 above, and begin recovers after 5 days, after 10 days a notable recuperation takes place. After 12 months no more deformation has been observed.

[0206] An elder patient with severe Depression (71 years old) was treated using method as N.sup.o 4 above, and begin recovers after 5 days, after 10 days a notable recuperation takes place. After 11 months no more Depression has been detected.

OTHERS REFERENCES

[0207] Troost et al. 1989. Clin. Neuropathol. 8:289-294. [0208] Engelthardt et al. 1990. Arch. Neurol. 47:1210-1216. [0209] Schiffer et al. 1996. J. Neurol. Sci. 139(suppl):27-33, [0210] Hayashi et al. 2001 J. Neurol. Sci. 188:3-7.9-12). [0211] Obal et al. 2001 Neuroreport. 12:2449-2452. [0212] Sola et al. 2002 8. Eur. Neurol. 47:108-112. [0213] Ono et al. 2001 J. Neurol. Sci. 187:27-34. [0214] Alexianu et al. 2001 Neurology. 57:1282-1289). [0215] Obal et al. 2001 Neuroreport. 12:2449-2452. [0216] McGeer et al. 2002 Muscle Nerve. 26:459-47028, 29. [0217] Moulignier et al. Reversible ALS-like disorder in HIV infection. Neurology. 57:995-1001, 2001 [0218] MacGrowen et al. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology. 2001, 57:1094-10. [0219] Power et al. 2001 Adv. Virus. Res. 56:389-433. [0220] Janssen et al. 1991, Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 41:778-785. [0221] McArthur et al. 1993 Multicenter AIDS Cohort Study. Neurology. 43:2245-2252; The Dana Consortium. 1996. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology. 47:1247-1253). [0222] Smits et al. 2000 Eur. J. Clin. Invest. 30:526-535. [0223] Fiala et al. 2002 Eur. J. Clin. Invest. 32:360-371. [0224] Minagar et al. 2002, The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202:13-23. [0225] Pulliam et al. 1997 Lancet. 349:692-695. [0226] Diesing et al. 2002 AIDS Reader. 12:358-368. [0227] Glass et al. 1995 Ann. Neurol. 38:755-762. [0228] Adamson et al. 1999 Mol. Med. 5:98-109. [0229] Williams et al. 2002, Am. J. Pathol. 161:575-585. [0230] Appel et al. Evidence for autoimmunity in ALS. J. Neurol. Sci. 118, (1993), pp. 169-174. [0231] J. I. Engelhardt, &It Appel, IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis, Arch. Neurol., 47 (1990), pp. 1210-1216 [0232] Liu et al. 2000 J. Neurovirol. 6(suppl 1): S70-81 [0233] J. O. Hernández, 2021, About neurodegenerative diseases, unpublished results [0234] Raja Bhattacharyya, Sophia E. Black, Madhura S. Lotlikar, Rebecca H. Fenn, Mehdi Jorfi, Dora M. Kovacs, Rudolph E. Axonal generation of amyloid-β from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes. Cell Reports, 2021; 35 [0235] Koos B J, Sameshima H, Power G G. Fetal breathing, sleep state, and cardiovascular responses to graded hypoxia in sheep. J Appl Physiol (1985) 1987 March; 62 (3):1033-1039. [0236] Silver, L, Erecinska, M. Oxygen and ion concentrations in normoxic and hypoxic brain cells. In Oxygen Transport to Tissue XX, 7-15, edited by Hudetz and Bruley, Plenum Press, New York (1988). [0237] Méndez E., Zeledón F., Zamora J., Cortés A., Rev. costarric. cardiol vol. 6 n. 1 San José, January 2004. [0238] Ganong W. F. Review of Medical Physiology. 19th ed. California, Appleton and Lange, 1999. [0239] Guyton A C, Hall J E. Textbook of Medical Physiology. 9th ed. Philadelphia, W. B. Saunders, 1996. [0240] Mathews, C. K., van Holde, K. E., Ahern K. G. Biochemistry. 3rd ed. Addison Wesley, California, 2002 [0241] Heppner, Nature neuro science, 2020. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals. [0242] Chen et al. Lancet. 2020 15-21 February; 395(10223): 507-513. Published online 2020 Jan. 30. Lymphocytopenia in patients with COVID19. [0243] Hellerstein M., Vaccine, Vol. 6 11 Dec. 2020, 100076. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Lymphocytopenia in patients with COVID19. (Chen et al. Lancet. 2020 15-21 February; 395(10223): 507-513. Published online 2020 Jan. 30.